Synthetic tetrapeptide studied in telomerase-related cell processes
Preclinical research
Read the profile Peptide profile
Elamipretide
Also known as SS-31
Mitochondria-targeting peptide that binds cardiolipin
Approved medicines exist
Science, with its context intact.What to knowThe evidence
The evidence
in perspective.
FDA granted accelerated approval to Forzinity in 2025 for a defined Barth syndrome population. Continued approval may depend on confirmatory evidence; general longevity benefits are not established.
View the supporting source- Research area
- Cellular
- Biological target or mechanism
- Mitochondria-targeting peptide that binds cardiolipin
- Evidence context
- Approved medicines exist
- Availability
- Availability requires pharmacy review
From information to a conversationClinical decisions stay
Clinical decisions stay
with clinical professionals.
This profile is a research reference. Your prescriber and pharmacy assess the relevant clinical and dispensing pathway. Inclusion here is not an offer to sell this compound.
Explore the same area.
All cellular profiles
Mitochondria-derived peptide studied in cellular survival and stress responses
Preclinical research
Read the profile